If you are currently attending PITTCON, stop by booth 4135 and say hi … and don’t forget Bruker’s annual PITTCON press conference, Tuesday, March 4, 2014, 12:00-1:15 pm at the Hyatt Regency McCormick. (Lunch will be served). To learn more or register, click here.
We’re introducing a range of new products at PITTCON, from all corners of the Bruker world, including NMR, GC-MS, FT-IR and MALDI-TOF:
TopSolids™ Software Provides Accelerated Workflow in Solid-State NMR for the Characterization of Protein Structures
TopSolids™ is a new intuitive, workflow-based software package for solid-state NMR in structural biology that provides menu-based, automated setup and acquisition of the most advanced multinuclear multi-dimensional NMR experiments.
Next-generation GC-APCI II GC-MS interface with automatic MS calibration for metabolomics and small molecule research
The GC-APCI II is designed to provide the best GC-MS performance together with dramatically improved usability. It allows smarter use of precious lab-space and saves time during operation. Unidentified GC peaks can now be routinely analyzed in UHR-MS systems.
MIR-FIR Spectroscopy in One Step: An FT-IR Dream Becomes a Reality
Introducing the world’s first FTIR spectrometer which covers the complete mid and far Infrared/THz spectral ranges in one step with no gaps! The new wide range MIR-FIR DLaTGS detector is combined with the recently introduced wide range MIR-FIR beamsplitter.
Bruker today announced the third release of its successful NMR JuiceScreenerTM. The new release comes with significant enhancements that enable the accurate, swift, automated screening of even more fruit juice types from just a single experiment.
autoflex™ speed MALDI-TOF(/TOF) with 2 kHz Smartbeam™ Laser
The new autoflexTM speed delivers superior performance by incorporating numerous innovative technology advancements which provide further enhanced data quality, acquisition speed, class-leading mass and dynamic range, and general robust and efficient performance.
PITTCON is all about laboratory science, and has become the largest conference dedicated to it. It’s Bruker’s platform for announcing our latest product innovations and showcasing our expanding portfolio of analytical technologies.
Looking back, PITTCON has always been a great show for Bruker. And in part, it’s because – like the conference – Bruker’s audience has grown to include the life sciences, drug discovery, QA, food safety, drug screening, and the environmental & bioterrorism markets – among others.
Bruker AXS will be running some excellent short courses, including:
- Introduction to Two-Dimensional X-ray Diffraction
X-ray diffraction (XRD) is a non-destructive, analytical method for characterization of materials of all kinds, such as metals, polymers, ceramics, semiconductors, thin films, biomaterials and composites. The advances in two-dimensional X-ray detectors has further enhanced the applications of XRD.
- Primer on XRF Spectrometry: Instrumentation
Due to its wide dynamic concentration range, simple sample preparations and least-cost-per-unit analysis, X-ray Fluorescence Spectrometry (XRF) has been widely used by many industry sectors, such as cement, steel, glass, petrochemicals, pharmaceuticals and mineral processing as a primary tool for QA/QC of their products.
- And other short courses, including: Basic User and Safety Training for Hand Held XRF (PXRF) in the Workplace, Practical Handheld (HH) XRF or Portable XRF in the Workplace and Screening for Restricted Materials (ROHS II) Using HH XRF.
Bruker Daltonics will be highlighting the latest, even more powerful mass spectrometry systems, and other teams from the Bruker family will feature their latest, marketing-changing analytical instrumentation.
For those interested in attending or learning more about Bruker’s annual press conference at PITTCON (Tuesday, March 4, 2014, 12:00-1:15 pm, Hyatt Regency McCormick, lunch served), you can learn more or register here.
If you’ll be attending PITTCON, stop by and visit us at Booth 4135 to learn about the extensive portfolio of powerful analytical technologies available under the Bruker brand.
Enjoy PITTCON, everyone!
The overwhelming majority of drugs on the market today are based on small molecules. And while biologics are becoming increasingly important – as are peptides (the smaller of which bridge the gap between small molecules and biologics) – small molecules remain the dominant active components of today’s drugs.
Even as therapeutic research targets have become smaller and more specific, the technology underpinning the research is being called upon to deliver bigger, more complex – and more complete – solutions. I’ve written before about the co-evolution of mass spec with life sciences research and the rise of ‘omics, and the field of small molecule research and development is no exception.
I’ve heard mass spec’s role in research discussed in terms of a “chicken-or-the-egg” kind of scenario: does research drive evolution of our technologies, or have emergent mass spec technologies made cutting edge research possible?
I suspect it’s a bit of both; the leading edge of research tends to drive future tech innovations, and those innovations help further push the boundaries of research. It’s a wonderfully symbiotic relationship!
Small Molecules – Cell Signaling Leads to Growing Computational Demands
Those in the field know that many aspects of small molecule pharma involve cell signaling. This means that the constituent molecule must be analyzed and understood thoroughly. Just as important is an understanding of the molecule’s effects on other biological functions. The result? Exponential growth in the amount of data to be gathered and analyzed.
In a post a few weeks back on metabolomics, I mentioned the importance of a combinatorial or complementary approach to analysis, with different systems providing complementary data to help form a bigger picture. Small molecule research is similar, with different technologies (e.g. ESI-TOF and MALDI imaging, or NMR) providing a much more comprehensive understanding of the molecule and its effects on other biological systems.
In Bruker’s case, the combination of MALDI imaging and FTMS posed a great solution to pharma’s need for
a high-performance imaging solution targeted specifically to the tissue distribution of small molecule drugs and metabolites, endogenous metabolic spatial profiling, and lipid imaging.
As small molecule research and development has evolved, mass spec technology has kept up in stride. Today’s small molecule research focuses on high speed, rapid & accurate characterization of enormous quantities of targets. Today’s systems are up to the challenge – delivering and analyzing more data, faster, at greater resolution, with more confidence, with maximum ease-of-use and more system flexibility than ever before.
What features of your mass spec system do you find most important for small molecule research?Read More
We’ve done a few posts about the power and versatility of Ion Trap mass spec, and we still sometimes field questions with a common theme:
Is Ion Trap still a really good technology?
How good is Ion Trap technology, really?
Really, is Ion Trap technology good?
Besides demonstrating a remarkable diversity in their sentence structure, the questions boil down to a simple thought: Ion Trap has been around for a while – how important is it today as an MS technology?
In a nutshell – Ion Trap is still the lab workhorse of mass spectrometers. Yes, different MS systems have different functions and specialties (e.g., MALDI imaging), but Ion Trap is the heart and soul of a great number of laboratories worldwide. I suppose it could be likened to the gasoline engine. Sure, there are applications for diesel – and hybrids and electric cars have taken a small piece of the market share – but gasoline engines are still the workhorses of our automotive infrastructure. Likewise with Ion Trap technology…it’s the primary MS technology that many labs turn to.
Ion Trap systems are uniquely powerful, fast and accurate – while still maintaining exquisite sensitivity for low levels of detection. Analyte quantification using Ion Traps is both accurate and reproducible for a variety of samples and matrices.
One immediate feature of the Ion Trap that comes to mind is its ability to achieve very definitive structural elucidation of unknowns using multiple stage mass spectrometry (MSn) by simply adding additional MS operations that will be performed sequentially. Multi-stage mass spectrometry – a huge advantage of Ion Trap MS – is like performing an FT-ICR reaction experiment – without the huge instrument, high price-tag and complicated use.
Best of all – especially for a laboratory workhorse system – ion traps typically have a compact mass analyzer design, which is ideal for customers with limited bench space.Read More
Comprehensive metabolomic profiling can serve as a window into the physiological functioning of an organism. Metabolomics provides a dynamic and quantitative view of the expression patterns and changing concentrations of all of the metabolites in a tissue, organ, or entire organism.
I read a great description of the power of metabolomics in an article from BioTechniques: “Metabolomics can therefore be seen as bridging the gap between genotype and phenotype, providing a more comprehensive view of how cells function, as well as identifying novel or striking changes in specific metabolites.
Metabolomic analysis provides a very accurate measure of even the slightest changes in an organism’s metabolite levels. It allows even subtle increases or decreases in the levels of one or several small molecules in the metabolomic fingerprint to be identified and potentially linked to specific phenotypic changes.
These perturbations and fluxes in small molecule concentrations may result from various or external factors, including genetic modifications, response to disease initiation or progression or to an injury or other traumatic event, therapeutic intervention, changes in diet or other lifestyle factors, or environmental variations such as exposure to toxins.
Integrated Metabolomic Solutions that Combine Complementary Technologies
Sensitive and accurate tools for metabolomic analysis must be able to detect very small changes in the physiologically important metabolites. I’m a broken record on the subject, but multiple integrated technologies should be brought to bear on the wide range of chemical structures to be analyzed. Detection, quantification and identification are best performed with complimentary systems that can identify as many metabolites as possible.
What Should a Comprehensive Metabolomics Solution Look Like?
An ideal integrated solution would bring together the latest innovations in hyphenated NMR, LC-MS, GC-MS, and FTIR technology with state-of-the-art computational tools and multivariate statistical methods. Such a solution would deliver valuable insights into the physiological response of an organism to internal and external stimuli.
Bruker’s Metabolic Profiler™, for example, was designed to deliver rapid biomarker detection, identification, and validation. The system combines the structural resolving power of NMR with the molecular identification capability of high resolution MS.
As I mentioned above, if you need a complete picture of the metabolome you have to have all the hardware and software puzzle pieces. An excellent example of another one of those components of a comprehensive metabolomics solution would be Bruker’s solariX XR Fourier Transform MS system, which utilizes the acclaimed ParaCell™ technology and eXtreme Resolution to achieve resolving power greater than 10 million and help deliver structural elucidation of unknowns.
Metabolomics is the art is probing deep into the chemical space. It demands different, complimentary technologies with high-resolving power, the collection of large amounts of complex data, and the application of sophisticated computational algorithms to analyze the data.
What tools do you use for targeted and non-targeted metabolomics studies?Read More
Bruker recently updated the Biotyper Reference Library to provide extended coverage of clinical and industrial important microbial organisms. The update included additional spectra for already listed species to further improve the MALDI Biotyper’s accuracy and speed of microbial IDs.
Learn more over at Mass Spectrometry News, or check out our press release.Read More
Metabolomics aims to achieve the comprehensive qualitative & quantitative analysis of the small molecules present in a cell, tissue or organism, and to understand their interplay in response various factors. Typically – during a Metabolomics study – many samples are analyzed and compared to identify possible biomarkers related to a disease, drug toxicity, or genetic or environmental variation.
It’s a field in which Bruker instruments excel: high sample throughputs, ultra-high high resolution, fast acquisition speeds…and combining multiple datasets for analysis.
The Challenge: Non-Targeted Metabolomics.
It’s the identification of unknown metabolites – known as non-targeted or untargeted metabolomics - however, that metabolomics researchers typically define as their greatest challenge. It’s a field requiring unique solutions that pull together complementary technologies… whether it’s TOF LC-MS, FTMS and MALDI, GC-MS or NMR.
We’re passionate about using complementary approaches to answer the scientific questions posed by fields such as metabolomics. In fact, bringing multiple techniques to bear has helped metabolomics play catch-up with the study of genomes, transcriptomes and proteomes – and allows researchers to construct more holistic pictures of biological systems.
Learn more about Bruker and non-targeted metabolomics.Read More